Platelet disorders: Pathology review

17,554views

Platelet disorders: Pathology review

Watch later

Watch later

Hypertension: Pathology review
Apnea, hypoventilation and pulmonary hypertension: Pathology review
Acute respiratory distress syndrome
Angina pectoris
Aortic valve disease
Arterial disease
Asthma
Atrial septal defect
Bronchiectasis
Chronic bronchitis
Chronic venous insufficiency
Coarctation of the aorta
Deep vein thrombosis
Emphysema
Endocarditis
Gas exchange in the lungs, blood and tissues
Heart failure
Mitral valve disease
Myocardial infarction
Patent ductus arteriosus
Pericarditis and pericardial effusion
Peripheral artery disease
Pleural effusion
Pneumonia
Pulmonary edema
Restrictive lung diseases
Shock
Stroke volume, ejection fraction, and cardiac output
Tetralogy of Fallot
Dementia: Pathology review
Anxiety disorders: Clinical
Arteriovenous malformation
Bipolar and related disorders
Cauda equina syndrome
Cranial nerves
Seizures and epilepsy
Generalized anxiety disorder
Headaches: Pathology review
Huntington disease
Ischemic stroke
Major depressive disorder
Meningitis
Migraine
Multiple sclerosis
Myasthenia gravis
Panic disorder
Parkinson disease
Stroke: Clinical
Alzheimer disease
Diabetes mellitus: Pathology review
Abnormal uterine bleeding: Clinical
Adrenocorticotropic hormone
Chlamydia trachomatis
Cortisol
Cushing syndrome
Endometriosis
Glucagon
Glucocorticoids
Herpes simplex virus
HIV (AIDS)
Hyperthyroidism: Pathology review
Hypothyroidism: Pathology review
Hypothyroidism
Insulin
Neisseria gonorrhoeae
Pelvic inflammatory disease
Polycystic ovary syndrome
Primary adrenal insufficiency
Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Testosterone
Thyroid hormones
Benign prostatic hyperplasia
Congenital adrenal hyperplasia
Waterhouse-Friderichsen syndrome
Hyperaldosteronism
Adrenal cortical carcinoma
Conn syndrome
Thyroglossal duct cyst
Hyperthyroidism
Graves disease
Thyroid eye disease (NORD)
Toxic multinodular goiter
Thyroid storm
Euthyroid sick syndrome
Hashimoto thyroiditis
Subacute granulomatous thyroiditis
Riedel thyroiditis
Thyroid cancer
Hyperparathyroidism
Hypoparathyroidism
Hypercalcemia
Hypocalcemia
Diabetes mellitus
Diabetic retinopathy
Diabetic nephropathy
Hyperpituitarism
Pituitary adenoma
Hyperprolactinemia
Prolactinoma
Gigantism
Acromegaly
Hypopituitarism
Pituitary apoplexy
Sheehan syndrome
Hypoprolactinemia
Constitutional growth delay
Diabetes insipidus
Precocious puberty
Delayed puberty
Premature ovarian failure
Androgen insensitivity syndrome
Kallmann syndrome
5-alpha-reductase deficiency
Autoimmune polyglandular syndrome type 1 (NORD)
Multiple endocrine neoplasia
Pancreatic neuroendocrine neoplasms
Zollinger-Ellison syndrome
Carcinoid syndrome
Pheochromocytoma
Neuroblastoma
Opsoclonus myoclonus syndrome (NORD)
Adrenal insufficiency: Pathology review
Adrenal masses: Pathology review
Thyroid nodules and thyroid cancer: Pathology review
Parathyroid disorders and calcium imbalance: Pathology review
Cushing syndrome and Cushing disease: Pathology review
Pituitary tumors: Pathology review
Hypopituitarism: Pathology review
Diabetes insipidus and SIADH: Pathology review
Multiple endocrine neoplasia: Pathology review
Chronic leukemia
Coagulation disorders: Pathology review
Disseminated intravascular coagulation
Factor V Leiden
Hemophilia
Hodgkin lymphoma
Non-Hodgkin lymphoma
Hypokalemia
Inflammation
Innate immune system
Introduction to the immune system
Iron deficiency anemia
Leukemias: Pathology review
Platelet disorders: Pathology review
Sickle cell disease (NORD)
Type IV hypersensitivity
Vaccinations
Acute cholecystitis
Acne vulgaris
Opioid antagonists
Opioid agonists, mixed agonist-antagonists and partial agonists
Opioid use disorder
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Anticoagulants: Direct factor inhibitors
Anticoagulants: Heparin
Anticoagulants: Warfarin
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Role of Vitamin K in coagulation
Vitamin B12 deficiency
Loop diuretics
Miscellaneous lipid-lowering medications
Potassium sparing diuretics
Adrenergic antagonists: Alpha blockers
Calcium channel blockers
Lipid-lowering medications: Fibrates
Lipid-lowering medications: Statins
Adrenergic antagonists: Beta blockers
Class II antiarrhythmics: Beta blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Class III antiarrhythmics: Potassium channel blockers
Class I antiarrhythmics: Sodium channel blockers
Thiazide and thiazide-like diuretics
ACE inhibitors, ARBs and direct renin inhibitors
Positive inotropic medications
Anthelmintic medications
Anti-mite and louse medications
Antimalarials
Hepatitis medications
Integrase and entry inhibitors
Antimetabolites: Sulfonamides and trimethoprim
Azoles
Cell wall synthesis inhibitors: Cephalosporins
Cell wall synthesis inhibitors: Penicillins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Echinocandins
Herpesvirus medications
Mechanisms of antibiotic resistance
Miscellaneous cell wall synthesis inhibitors
Miscellaneous protein synthesis inhibitors
Neuraminidase inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Protein synthesis inhibitors: Aminoglycosides
Protein synthesis inhibitors: Tetracyclines
Antihistamines for allergies
Miscellaneous antifungal medications
Androgens and antiandrogens
Aromatase inhibitors
Estrogens and antiestrogens
PDE5 inhibitors
Progestins and antiprogestins
Uterine stimulants and relaxants
Acid reducing medications
Antidiarrheals
Laxatives and cathartics
Non-corticosteroid immunosuppressants and immunotherapies
Hyperthyroidism medications
Hypoglycemics: Insulin secretagogues
Hypothyroidism medications
Insulins
Miscellaneous hypoglycemics
Mineralocorticoids and mineralocorticoid antagonists
Sympatholytics: Alpha-2 agonists
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Atypical antipsychotics
Atypical antidepressants
Typical antipsychotics
Lithium
Monoamine oxidase inhibitors
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Tricyclic antidepressants
Anti-parkinson medications
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Muscarinic antagonists
Headaches: Clinical
Migraine medications
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Folate (Vitamin B9) deficiency

Transcript

Watch video only

At the family medicine center, a mother came in with her 5 year old child, Alana.

Several days ago, Alana developed bloody diarrhea after eating undercooked ground beef and her mother noticed her face was pale and she only urinated once in the past 12 hours.

Next to her, there’s a 30 year old person named Danika, who came in complaining of increased bruising for the past several months.

She has no other symptoms and physical examination shows multiple ecchymoses on the extremities.

Both Alana and Danika are suffering from a hemostasis disorder.

Hemostasis disorders, also known as bleeding disorders, can be broadly divided into three groups.

The first includes problems with primary hemostasis, which is when there’s a problem forming the initial platelet plug, and so, they’re referred to as platelet disorders.

Now, the second group includes problems with secondary hemostasis, which is making a strong fibrin clot through activation of the intrinsic, extrinsic and common coagulation pathways, and are also known as coagulation disorders.

And the last group includes disorders that affect both primary and secondary hemostasis and are known as mixed platelet and coagulation disorders.

For this video, let’s focus on the platelet disorders.

These can be further subdivided into two categories. In the first category, there’s thrombocytopenia, which is defined as a platelet count below 150,000 per microliter, with the normal range being between 150,000 and 450,000.

Thrombocytopenia can be caused by increased platelet destruction, which can be immune-mediated, like in heparin induced thrombocytopenia, or HIT, and immune thrombocytopenic purpura, or ITP.

Other cases can be non-immune mediated, like thrombotic thrombocytopenic purpura, or TTP, and hemolytic-uremic syndrome, or HUS.

Thrombocytopenia from these cases is often due to an increased consumption of platelets during the formation of abnormal clots.

And as a result, there are fewer platelets left in circulation.

Alright, now, in the second category of platelet disorders, there’s a decrease in platelet function, while the platelet count can be normal, like in Glanzmann thrombasthenia, Bernard-Soulier syndrome, and uremic platelet dysfunction.

Okay, so let’s take a closer look at these different platelet disorders, starting with the immune-mediated causes of platelet destruction.

First, there’s heparin induced thrombocytopenia, or HIT, which is a reaction that develops 5 to 15 days after starting either unfractionated or low-molecular weight heparin.

Remember for your exams that the risk for HIT is greater with unfractionated heparin.

HIT is caused by an IgG antibody that binds to an antigen complex made of heparin and the endogenous cytokine platelet factor 4.

The antibody then binds to and activates platelets, causing them to get used up when they form numerous blood clots.

Alright, next we have immune thrombocytopenic purpura, or ITP. ITP is caused by autoantibodies that bind to the platelet receptor GpIIbIIIa, and target platelets for destruction in the spleen.

It’s like the platelet equivalent of autoimmune hemolytic anemia, where antibodies and complement are directed against RBCs, targeting them for destruction.

In fact, some patients develop both conditions together and that’s called Evan’s syndrome.

When ITP occurs by itself, it’s called primary ITP, but when it’s triggered by another condition like hepatitis C, HIV, or lupus - it’s called secondary ITP.

Now, let’s move onto non-immune mediated causes of platelet destruction.

So, normally, endothelial cells store and release Von Willebrand factor, which serves as the glue between the platelet receptor GpIb and the collagen underneath the endothelial cells.

Many individual von willebrand factors can clump together, forming large multimers.

Eventually, to prevent the clot from getting too big, a metalloproteinase called ADAMTS-13 comes along and breaks down the multimers.

In thrombotic thrombocytopenic purpura, or TTP, there can be a genetic deficiency of ADAMTS-13, or an autoantibody against ADAMTS-13.

Sometimes autoantibodies to ADAMTS-13 develop after exposure to antiplatelet medications like ticlopidine and clopidogrel, or chemotherapeutic agents like cyclosporine and gemcitabine.

Alternatively, they can be associated with diseases like systemic lupus erythematosus.

Ultimately, the result is an accumulation of von willebrand factor multimers, and that causes excessive platelet adhesion and clot formation within small blood vessels throughout the body.

Alright, now HUS is clinically similar to TTP, and there are two types of HUS; typical and atypical. The typical type is also called shiga-toxin producing Escherichia coli HUS, or SPEC-HUS.

It classically occurs in children and develops after an episode of gastroenteritis caused by shiga toxin producing organisms, like enterohemorrhagic Escherichia coli subtype O157:H7 and Shigella dysenteriae.

This shiga toxin destroys colonic epithelial cells, causing bloody diarrhea.

It then enters the circulation, where it damages the endothelial cells, triggering a massive release of von willebrand factor.

This leads to excessive platelet adhesion, and clot formation throughout the body.

Typical HUS carries a good prognosis and usually isn’t life-threatening.

On the other hand, atypical HUS is not associated with shiga-toxin producing Escherichia coli, may occur at any age, and has a relatively poor prognosis.

Atypical HUS is linked to a genetic mutation in factor H, a protein that normally controls the complement system.

Without factor H, the complement system goes wild, causing damage to the endothelial cells.

Okay, now let’s move onto disorders with platelet dysfunction.

Glanzmann thrombasthenia is an autosomal recessive bleeding disorder.

The term thrombasthenia literally means “weak platelets”.

And it’s caused by a deficiency in the platelet receptor GpIIbIIIa, which is necessary for platelets to stick to each other via fibrin.

So even though the platelet count can be normal, there’s diminished platelet aggregation.

Moving on, Bernard-Soulier is a rare autosomal recessive disorder caused by a deficiency or absence of the platelet receptor GpIb.

GpIb normally binds to von Willebrand factor which it self is bound to the collagen exposed in the damaged endothelial lining.

So here, platelets can’t adhere to the damaged blood vessels and they won’t activate the platelet plug formation process.

Finally, there’s uremic platelet dysfunction which occurs in individuals with chronic kidney disease.

The pathophysiology isn’t fully understood, but it’s thought that there’s an accumulation of toxins which interferes with the normal platelets - endothelium interaction.

Whatever the cause, platelet problems, or primary hemostatic disorders, usually present with petechiae, which are pinpoint superficial skin bleeds, anterior epistaxis, which are usually mild nosebleeds, immediate bleeding after surgical procedures, like tooth extraction, or bleeding from mucosal surfaces, like gingival, gastrointestinal, or vaginal bleeding.

Now, when there’s thrombocytopenia like in ITP, the lower the platelet count, the higher the risk of bleeding or bruising.

Spontaneous bleeds start to happen when the platelet count falls below 30,000, with spontaneous intracranial bleeds developing when the platelet count falls below 10,000.

Finally, most surgical procedures can be performed as long as the platelet count is above 50,000.

Alright, but other symptoms can help you identify the specific disease.

Let’s start with HIT, which is the most common cause of thrombocytopenia in hospitalized individuals.

For your exams, it’s important to know that individuals with HIT more often develop paradoxical thrombotic events, rather than bleeding.

Thrombotic events can be life threatening and are most often venous, causing deep vein thrombosis, pulmonary embolism, or cerebral venous sinus thrombosis or less often arterial, causing limb gangrene, stroke, or myocardial infarction.

Other individuals simply have thrombocytopenia on a CBC.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  5. "Williams Hematology, Eighth Edition" McGraw-Hill Education / Medical (2010)
  6. "Heparin induced thrombocytopenia: diagnosis and management update" Postgraduate Medical Journal (2007)
  7. "The management of heparin-induced thrombocytopenia" British Journal of Haematology (2006)
  8. "Management of Adult Idiopathic Thrombocytopenic Purpura" Annual Review of Medicine (2005)
  9. "ABC of clinical haematology: Platelet disorders" BMJ (1997)
  10. "Syndromes of Thrombotic Microangiopathy" Medical Clinics of North America (2017)
  11. "Thrombotic Microangiopathies" New England Journal of Medicine (2002)
  12. "Hemolytic Uremic Syndrome: New Developments in Pathogenesis and Treatment" International Journal of Nephrology (2011)
  13. "Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models" Blood (2011)
  14. "Amelioration of the macrothrombocytopenia associated with the murine Bernard-Soulier syndrome" Blood (2002)
  15. "Platelet Dysfunction in Renal Failure" Seminars in Thrombosis and Hemostasis (2004)